ASCO GUIDELINES Bundle

Salivary Gland Malignancy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/1475500

Contents of this Issue

Navigation

Page 1 of 7

Key Points ➤ Because salivary gland malignancies (SGMs) account for less than 5% of all head and neck cancers, there are limited clinical trial data to help guide therapy. ➤ Optimal treatment requires appropriate pathologic technique to differentiate among the wide spectrum of histologies and the variety of biological behaviors seen in SGMs. Management Preoperative Evaluation ➤ Providers should perform imaging (neck ultrasound, CT with IV contrast and/or MRI of the neck and primary site) in patients with a suspicion of a salivary gland cancer. (Strong recommendation; EB-I) ➤ Providers should perform computed tomography of the neck with IV contrast for patients with suspicion for salivary gland cancer and involvement of adjacent bone. (Strong recommendation; EB-I) ➤ Providers should perform contrast-enhanced MRI with a diffusion sequence of the neck and skull base for patients with suspicion for salivary gland cancer with concern for perineural invasion and/or skull base involvement. (Strong recommendation; EB-I) ➤ Providers may perform a CT/positron emission tomography from the skull base to mid-thighs for patients with advanced stage high-grade salivary gland cancers. (Weak recommendation; EB-L) ➤ Providers should perform a tissue biopsy (either fine needle aspiration biopsy or core needle biopsy) in order to support distinction of salivary gland cancers from non-malignant salivary lesions. (Strong recommendation; EB-H) ➤ Providers may perform core needle biopsy if fine needle aspiration biopsy is inadequate or subsite precludes fine needle aspiration biopsy such as deep minor salivary glands. (Moderate recommendation; EB-L) ➤ Pathologists should report risk of malignancy using a risk stratification scheme for salivary fine needle aspiration biopsies with particular attention to high-grade features. (Strong recommendation; EB-I) ➤ Pathologists may perform ancillary testing (immunohistochemical or molecular studies) on fine needle aspiration biopsies and core needle biopsies to support diagnosis and risk of malignancy. (Weak recommendation; EB-L)

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Salivary Gland Malignancy